Head-to-head · free

Lexeo Therapeutics, Inc. Common Stock vs MiniMed Group, Inc.

LXEO vs MMED — return on capital, cash generation, margins and balance sheet side by side.

LXEO

3 / 4

measures where LXEO leads

MMED

1 / 4

measures where MMED leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureLXEO · FY2025MMED · FY2026
Revenue—$3.1B
Net income(100.0M)(333.0M)
Revenue growth (yearly, multi-year)——
Free cash flow(99.0M)(420.0M)
Free cash flow margin—-13.5%
Net cash / (debt)——
ROIC——
Return on equity-55.0%-9.6%
Gross margin—54.2%
Operating margin—-5.1%
Net debt / EBITDA0.59x4.74x

Figures are as reported by each company; latest fiscal year shown.

Where Lexeo Therapeutics, Inc. Common Stock's cash went (FY2025)

Capital spending
$397000
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LXEO profile →

Where MiniMed Group, Inc.'s cash went (FY2026)

Capital spending
$223.0M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MMED profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons